{{medical}}
{{expert|time=2017-11-14T00:09:55+00:00}}
{{inappropriate tone|time=2017-11-14T00:09:55+00:00}}
{{Taxobox
| color = lightgray
| image = Enterococcus_histological_pneumonia_01.png
| image_width = 240px
| image_caption = 感染肺部組織的''Enterococcus sp.''
| regnum = [[Bacteria|Bacteria]]
| divisio = [[Firmicutes|Firmicutes]]
| classis = [[Bacilli|Bacilli]]
| ordo = [[Lactobacillales|Lactobacillales]]
| familia = [[Enterococcaceae|Enterococcaceae]]
| genus = '''肠球菌屬''' '''''Enterococcus'''''
| genus_authority = (''ex'' Thiercelin & Jouhaud 1903)<br>Schleifer & Kilpper-Bälz 1984
| subdivision_ranks = Species
| subdivision =
''[[Enterococcus_malodoratus|E. malodoratus]]''<br/>
''[[Enterococcus_avium|E. avium]]''<br/>
''[[Enterococcus_durans|E. durans]]''<br/>
''[[Enterococcus_faecalis|E. faecalis]]''<br/>
''[[Enterococcus_faecium|E. faecium]]''<br/>
''[[Enterococcus_gallinarum|E. gallinarum]]''<br/>
''[[Enterococcus_hirae|E. hirae]]''<br/>
''[[Enterococcus_solitarius|E. solitarius]]''<br/>
etc.
}}
'''腸球菌屬'''（學名：''Enterococcus''），[[革蘭氏陽性|革蘭氏陽性]][[球菌|球菌]]。經常以成對（[[雙球菌|雙球菌]]）或短鏈方式存在，故從形態上與[[鏈球菌屬|鏈球菌屬]]很難區分<ref name=Gilmore_2002>{{cite book | title=The Enterococci: Pathogenesis, Molecular Biology, and Antibiotic Resistance | publisher = ASM Press | location=Washington, D.C. | year=2002 | author=Gilmore MS, et al. | isbn=978-1-55581-234-8}}</ref>。在人類腸道裡有兩種常見的[[偏利共生|偏利共生]]腸球菌：[[糞腸球菌|糞腸球菌]]（''Enterococcus faecalis''）約佔90-95%和[[屎腸球菌|屎腸球菌]]（''Enterococcus faecium''）約佔5-10%。其他人體中較少見的菌群還有''E. casseliflavus''、''E. gallinarum''和''E. raffinosus''<ref name=Gilmore_2002/>''。''腸球菌因為能生成抵抗藥物的物質，使它們不容易被抗生素殺死，且容易散播抗藥性並可在惡劣環境中生存，故近年來已成為臨床感染的重要致病菌之一<ref>{{Cite journal|title=The rise of the Enterococcus: beyond vancomycin resistance|url=https://www.ncbi.nlm.nih.gov/pubmed/22421879|last=Arias|first=Cesar A.|last2=Murray|first2=Barbara E.|date=2012-03-16|journal=Nature Reviews. Microbiology|issue=4|doi=10.1038/nrmicro2761|volume=10|pages=266–278|issn=1740-1534|pmc=3621121|pmid=22421879}}</ref><ref>{{Cite journal|title=Genetic differences in inhibition of 2-aminofluorene N-acetyltransferase activity between C57BL/6J and A/J mice|url=https://www.ncbi.nlm.nih.gov/pubmed/3485979|last=Hultin|first=T. A.|last2=Weber|first2=W. W.|date=1986-04-01|journal=Biochemical Pharmacology|issue=7|volume=35|pages=1214–1216|issn=0006-2952|pmid=3485979}}</ref><ref>{{Cite journal|title=Enterococcus faecalis as multidrug resistance strains in clinical isolates in Imam Reza Hospital in Kermanshah, Iran|url=https://www.ncbi.nlm.nih.gov/pubmed/26738400|last=Mohammadi|first=F.|last2=Ghafourian|first2=S.|date=2015|journal=British Journal of Biomedical Science|issue=4|volume=72|pages=182–184|issn=0967-4845|pmid=26738400|last3=Mohebi|first3=R.|last4=Taherikalani|first4=M.|last5=Pakzad|first5=I.|last6=Valadbeigi|first6=H.|last7=Hatami|first7=V.|last8=Sadeghifard|first8=N.}}</ref><ref>{{Cite journal|title=Investigation of mechanisms and molecular epidemiology of linezolid nonsusceptible Enterococcus faecalis isolated from a teaching hospital in China|url=https://www.ncbi.nlm.nih.gov/pubmed/26210761|last=Li|first=Bin|last2=Ma|first2=Chuan-Ling|date=August 2016|journal=Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi|issue=4|doi=10.1016/j.jmii.2015.05.010|volume=49|pages=595–599|issn=1995-9133|pmid=26210761|last3=Yu|first3=Xiao|last4=Sun|first4=Yao|last5=Li|first5=Mei-Mei|last6=Ye|first6=Jian-Zhong|last7=Zhang|first7=Ya-Pei|last8=Wu|first8=Qing|last9=Zhou|first9=Tie-Li}}</ref><ref>{{Cite journal|title=The changing epidemiology of bacteraemias in Europe: trends from the European Antimicrobial Resistance Surveillance System|url=https://www.ncbi.nlm.nih.gov/pubmed/23039210|last=de Kraker|first=M. E. A.|last2=Jarlier|first2=V.|date=September 2013|journal=Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|issue=9|doi=10.1111/1469-0691.12028|volume=19|pages=860–868|issn=1469-0691|pmid=23039210|last3=Monen|first3=J. C. M.|last4=Heuer|first4=O. E.|last5=van de Sande|first5=N.|last6=Grundmann|first6=H.}}</ref><ref>{{Cite journal|title=Public Health Risks of Multiple-Drug-Resistant Enterococcus spp. in Southeast Asia|url=https://www.ncbi.nlm.nih.gov/pubmed/26150452|last=Daniel|first=Diane Sunira|last2=Lee|first2=Sui Mae|date=September 2015|journal=Applied and Environmental Microbiology|issue=18|doi=10.1128/AEM.01741-15|volume=81|pages=6090–6097|issn=1098-5336|pmc=4542241|pmid=26150452|last3=Dykes|first3=Gary A.|last4=Rahman|first4=Sadequr}}</ref>。尤其是''E. faecium''經常對[[氨苄青黴素|氨苄青黴素]]（ampicillin）及[[萬古黴素|萬古黴素]]（vancomycin）具有[[抗藥性|抗藥性]]，是所有腸球菌感染症中最難治療的。

== 分類 ==
腸球菌是一種移生在腸道的[[革蘭氏陽性菌|革蘭氏陽性菌]]，故名腸球菌。在19世紀末發現，早期歸為[[鏈球菌屬|鏈球菌屬]]。1930年代中期，依蘭斯菲爾德血清分型（Lancefield classification），腸球菌被歸類為D群鏈球菌（Group D ''Streptococcus''），但是與非腸球菌的D群鏈球菌，如''Streptococcus bovis''， 在生化特性上有相當大的差異。直到1984年，基因體DNA分析指出腸球菌和鏈球菌的不同，而將腸球菌獨立成為一屬。<ref>{{cite journal|title=Transfer of ''Streptococcus faecalis'' and ''Streptococcus faecium'' to the genus ''Enterococcus'' nom. rev. as ''Enterococcus faecalis'' comb. nov. and ''Enterococcus faecium'' comb. nov.|url=http://ijs.microbiologyresearch.org/content/journal/ijsem/10.1099/00207713-34-1-31|author=Schleifer KH; Kilpper-Balz R|journal=Int. J. Sys. Bacteriol.|issue=|doi=10.1099/00207713-34-1-31|year=1984|volume=34|pages=31–34}}</ref>。

==  生理學 ==

腸球菌在顯微鏡下典型的排列為成對或短鏈狀，很難與[[肺炎鏈球菌|肺炎鏈球菌]]區別。腸球菌是[[兼性厭氧菌|兼性厭氧菌]]，可在有氧和無氧的環境中生長<ref name="Fischetti_2000">{{cite book|title=Gram-Positive Pathogens|publisher=ASM Press|year=2000|isbn=1-55581-166-3|editor=Fischetti VA, Novick RP, Ferretti JJ, Portnoy DA, Rood JI}}</ref>。 雖然腸球菌不能形成孢子，但他們對於生長環境卻有很高的耐受性，例如可在下列環境中生長：溫度10-45℃、酸鹼度pH 4.5-10.0、高鹽濃度6.5%NaCl或40%膽汁<ref name=Fisher_2009>{{Cite journal | title=The ecology, epidemiology and virulence of Enterococcus | author = Fisher K, Phillips C | journal = Microbiology | volume = 155 | issue = Pt6 | pages = 1749-57 |date= 2009  | pmid = 11120989 | pmid = 19383684 | doi =10.1099/mic.0.026385-0 }}</ref>。最適宜生長溫度為35℃，24小時培養可以形成白色菌落。

== 病理學 ==

腸球菌在臨床上引起的重要感染包括[[泌尿道感染|泌尿道感染]]、[[菌血症|菌血症]]、心內膜炎、憩室炎和[[腦膜炎|腦膜炎]]等<ref name="Fisher_2009"/><ref name=Sherris/> 。敏感性菌株的感染可用[[氨苄青黴素|氨苄青黴素]]（ampicillin）、[[青黴素|青黴素]]（penicillin）和[[萬古黴素|萬古黴素]]（vancomycin）治療<ref name=Baron>{{cite book | author = Pelletier LL Jr. | title = Microbiology of the Circulatory System. ''in:'' Baron's Medical Microbiology (Baron S et al., eds.)| edition = 4th | publisher = Univ of Texas Medical Branch | year = 1996 | url = http://www.ncbi.nlm.nih.gov/books/bv.fcgi?rid=mmed.section.5077 | isbn = 0-9631172-1-1 }}</ref>。 泌尿道感染則可用[[呋喃妥因|呋喃妥因]]（nitrofurantoin）進行特異性治療，即使在萬古黴素抗藥性的情況下<ref name="pmid11120989">{{cite journal | author = Zhanel GG, Hoban DJ, Karlowsky JA | title = Nitrofurantoin is active against vancomycin-resistant enterococci | journal = Antimicrob. Agents Chemother. | volume = 45 | issue = 1 | pages = 324–6 |date=January 2001  | pmid = 11120989 | pmc = 90284 | doi = 10.1128/AAC.45.1.324-326.2001 | url = }}</ref>。

從醫學觀點來看，腸球菌的一個重要特性是具有高度的先天[[抗藥性|抗藥性]]。一些腸球菌對[[β-內醯胺類抗生素|β-內醯胺類抗生素]]（β-lactam，如青黴素、[[頭孢菌素|頭孢菌素]]（cephalosporin）、碳青黴烯（carbapenem）及許多[[氨基糖苷類抗生素|氨基糖苷類抗生素]]（aminoglycoside）具有抗藥性<ref name="Sherris" />。尤其是過去20多年來，[[抗萬古黴素腸球菌|抗萬古黴素腸球菌]]（Vancomycin-Resistant ''Enterococcus''，VRE）在[[院內感染|院內感染]]患者逐漸被檢出，尤其是在美國<ref name="Fisher_2009"/>。[[抗萬古黴素腸球菌|抗萬古黴素腸球菌]]可用奎奴普丁/達福普丁（quinupristin/dalfopristin）來治療，約有70％的患者會達到治療效果<ref name="Tünger_2004">{{cite journal |author=Tünger A, Aydemir S, Uluer S, Cilli F |title=In vitro activity of linezolid & quinupristin/dalfopristin against Gram-positive cocci |url=https://www.ncbi.nlm.nih.gov/pubmed/15654141|journal=Indian J Med Res |volume=120 |issue=6 |pages=546–52 |year=2004 |pmid=15654141}}</ref>，若與[[去氧羥四環素|去氧羥四環素]]（doxycycline）合併治療，可降低抗藥性發生的機會。老虎黴素類抗生素（tigecycline）也已證明能用來治療腸球菌感染，如[[利福平|利福平]]（rifampicin）<ref>{{Cite journal | title=Therapeutic potential of rifampin in enterococcal infections | author = Moellering RC Jr, Wennersten C | journal = Rev Infect Dis | volume = 5 Suppl 3 | pages = S528-32 |year= 1983 Jul-Aug |url = https://www.ncbi.nlm.nih.gov/pubmed/6415781|pmid =  | doi = }}</ref>。

2008年的一研究分析了歐洲各國（北歐、英國、愛爾蘭、法國、中歐、南歐、東歐、荷蘭）[[抗萬古黴素腸球菌|抗萬古黴素腸球菌]]的發生與流行，並對臨床上預防[[抗萬古黴素腸球菌|抗萬古黴素腸球菌]]的方式提出建議。此篇文獻認為，''E. faecium''的氨苄青黴素（ampicillin）抗藥性可做為[[抗萬古黴素腸球菌|抗萬古黴素腸球菌]]風險一個很好的篩檢方法；對於分析''E. faecium''的基因差異（如''esp''基因、''pruK''基因）則屬次要的方式，因為這些基因學的特徵並非在所有抗氨苄青黴素（ampicillin）的''E. faecium''皆有一致的表現。也就是說，若沒有檢測出這些基因變異，並不能證明''E. faecium''菌株不會有擴散或導致疾病的風險<ref>{{Cite journal|title=Emergence and spread of vancomycin resistance among enterococci in Europe|url=https://www.ncbi.nlm.nih.gov/pubmed/19021959|last=Werner|first=G.|last2=Coque|first2=T. M.|date=2008-11-20|journal=Euro Surveillance: Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin|issue=47|volume=13|issn=1560-7917|pmid=19021959|last3=Hammerum|first3=A. M.|display-authors=3|last4=Hope|first4=R.|last5=Hryniewicz|first5=W.|last6=Johnson|first6=A.|last7=Klare|first7=I.|last8=Kristinsson|first8=K. G.|last9=Leclercq|first9=R.}}</ref>。[[世界衛生組織|世界衛生組織]]（WHO）在2017年初將[[抗萬古黴素腸球菌|抗萬古黴素腸球菌]]列為「高度威脅」的致病菌<ref>{{Cite journal|title=Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. World Health Organization; 2017 Feb 27.|url=http://www.who.int/medicines/publications/WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf}}</ref>。

腸球菌性[[腦膜炎|腦膜炎]]是神經外科上罕見的併發症。它一般需要透過靜脈或鞘內萬古黴素來進行治療，但是治療效果仍有爭議<ref name="Guardado_2006">{{cite journal |author=Guardado R |title=Post-surgical enterococcal meningitis: clinical and epidemiological study of 20 cases |url=https://www.ncbi.nlm.nih.gov/pubmed/16857599 |journal=Scand. J. Infect. Dis. |volume=38 |issue=8 |pages=584–8 |year=2006 |pmid=16857599 |doi=10.1080/00365540600606416 |author2=Asensi V |author3=Torres JM |display-authors=3 |last4=Pérez |first4=F. |last5=Blanco |first5=A. |last6=Maradona |first6=J. |last7=Cartón |first7=J.}}</ref>。新的流行病學證據顯示，腸球菌亦是慢性細菌性[[攝護腺炎|攝護腺炎]]的主要感染因子，腸球菌會在攝護腺中形成生物膜，使其難以治療。

除了抗藥性，腸球菌也會生成許多毒性因子，毒性因子是作用於人體且會引發許多病灶，甚至造成嚴重疾病的物質；這些因子皆增加了腸球菌對人體的致病力<ref>{{Cite journal|title=Enterococcus in wound infections: virulence and antimicrobial resistance|url=https://www.ncbi.nlm.nih.gov/pubmed/22750786|last=Dworniczek|first=Ewa|last2=Piwowarczyk|first2=Justyna|date=June 2012|journal=Acta Microbiologica Et Immunologica Hungarica|issue=2|doi=10.1556/AMicr.59.2012.2.11|volume=59|pages=263–269|issn=1217-8950|pmid=22750786|last3=Bania|first3=Jacek|display-authors=3| last4=Kowalska-Krochmal|first4=Beata|last5=Wałecka|first5=Ewa|last6=Seniuk|first6=Alicja|last7=Dolna|first7=Izabela|last8=Gościniak|first8=Grażyna}}</ref><ref>{{Cite journal|title=Drug resistance & virulence determinants in clinical isolates of Enterococcus species|url=https://www.ncbi.nlm.nih.gov/pubmed/23760387|last=Fernandes|first=Sanal C.|last2=Dhanashree|first2=B.|date=May 2013|journal=The Indian Journal of Medical Research|issue=5|volume=137|pages=981–985|issn=0971-5916|pmc=3734693|pmid=23760387}}</ref><ref>{{Cite journal|title=Molecular characterization of resistance, virulence and clonality in vancomycin-resistant Enterococcus faecium and Enterococcus faecalis: A hospital-based study in Beijing, China|url=https://www.ncbi.nlm.nih.gov/pubmed/25976380|last=Yang|first=Jing-xian|last2=Li|first2=Tong|date=July 2015|journal=Infection, Genetics and Evolution: Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases|doi=10.1016/j.meegid.2015.05.012|volume=33|pages=253–260|issn=1567-7257|pmid=25976380|last3=Ning|first3=Yong-zhong|display-authors=3|last4=Shao|first4=Dong-hua|last5=Liu|first5=Jing|last6=Wang|first6=Shu-qin|last7=Liang|first7=Guo-wei}}</ref>。

美國國家[[院內感染|院內感染]]監視系統（NNIS）所建置的國家健康照護安全網路（NHSN）<ref>{{cite journal|title=NHSN Annual Reports|url=https://www.cdc.gov/nhsn/datastat/index.html}}</ref>統計發現，腸球菌是[[院內感染|院內感染]]的第二大病原菌<ref>{{cite journal|title=Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010.|url=https://www.ncbi.nlm.nih.gov/pubmed/23221186|author1=Sievert DM | author2=Ricks P | author3=Edwards JR |display-authors=3 | author4=Schneider A| journal=Infect Control Hosp Epidemiol.|doi=10.1086/668770|year=2013|volume=34|issue=1|pages=1–14}}</ref>，且位居醫療照護相關血液感染比例的第三位<ref>{{cite journal|title=The CDC definition of mucosal barrier injury–associated bloodstream infection improves accurate detection of preventable bacteremia rates at a pediatric cancer center in a low- to middle-income country|url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4818654/|author1=Dara Torres | author2= Miriam Gonzalez | author3= Adriana Loera |display-authors=3 | author4=Marco Aguilera | journal=Am J Infect Control. |doi= 10.1016/j.ajic.2015.11.007|year=2016|volume=44|issue=4|pages=432–437}}</ref>，顯示腸球菌抗藥性所隱藏的致病風險。

{{Infobox disease
 | Name           = Enterococcus
 | Image          =
 | Caption        =
 | DiseasesDB     =
 | ICD10          =
 | ICD9           = {{ICD9|041.04}}
 | ICDO           =
 | OMIM           =
 | MedlinePlus    =
 | eMedicineSubj  =
 | eMedicineTopic =
 | MeshID         =
}}

== 食品應用 ==

=== 做為益生菌食用 ===
腸球菌是人類和許多動物的一種腸道共生菌，糞腸球菌和屎腸球菌是最常見的菌種，這兩種腸球菌已有許多研究證明其促進人體和動物（豬、家禽等）健康的功效，因此在保健食品的應用上普遍被作為[[益生菌|益生菌]]使用<ref>{{Cite journal|title=Probiotic Enterococcus faecium CRL 183 inhibit chemically induced colon cancer in male Wistar rats|url=https://link.springer.com/article/10.1007/s00217-008-0927-6|last=Sivieri|first=K.|last2=Spinardi-Barbisan|first2=A. L. T.|date=2008-12-01|journal=European Food Research and Technology|issue=2|doi=10.1007/s00217-008-0927-6|volume=228|pages=231–237|language=en|issn=1438-2377|last3=Barbisan|first3=L. F.|last4=Bedani|first4=R.|last5=Pauly|first5=N. D.|last6=Carlos|first6=I. Z.|last7=Benzatti|first7=F.|last8=Vendramini|first8=R. C.|last9=Rossi|first9=E. A.}}</ref><ref>{{Cite journal|title=Discontinuous DNA replication in mouse P-815 cells|url=https://www.ncbi.nlm.nih.gov/pubmed/1168572|last=Gautschi|first=J. R.|last2=Clarkson|first2=J. M.|date=1975-01-02|journal=European Journal of Biochemistry|issue=2|volume=50|pages=403–412|issn=0014-2956|pmid=1168572}}</ref><ref>{{Cite journal|title=Coexistence of acute leukemia and gastric cancer in advanced ages|url=https://www.ncbi.nlm.nih.gov/pubmed/3476767|last=Kato|first=Y.|last2=Okazaki|first2=T.|date=April 1987|journal=[Rinsho Ketsueki] The Japanese Journal of Clinical Hematology|issue=4|volume=28|pages=608–615|issn=0485-1439|pmid=3476767|last3=Mochizuki|first3=T.|last4=Tashima|first4=M.|last5=Sawada|first5=H.|last6=Uchino|first6=H.|last7=Obayashi|first7=T.}}</ref><ref>{{Cite journal|title=Immediate results of treatment of children with complicated forms of primary tuberculosis|url=https://www.ncbi.nlm.nih.gov/pubmed/5300979|last=Griko|first=S. P.|date=1966|journal=Problemy Tuberkuleza|issue=3|volume=44|pages=33–37|issn=0032-9533|pmid=5300979}}</ref><ref>{{Cite journal|title=Effect of a new fermented soy milk product on serum lipid levels in normocholesterolemic adult men|url=https://www.ncbi.nlm.nih.gov/pubmed/12942871|last=Rossi|first=Elizeu Antonio|last2=Vendramini|first2=Regina Célia|date=March 2003|journal=Archivos Latinoamericanos De Nutricion|issue=1|volume=53|pages=47–51|issn=0004-0622|pmid=12942871|last3=Carlos|first3=Iracilda Zeppone|last4=de Oliveira|first4=Maurício Gonçalves|last5=de Valdez|first5=Graciela Font}}</ref><ref>Enterococcus organisms and their use as probiotics in alleviating irritable bowel syndrome symptoms. ''European Patent 0508701 (B1),1996.''</ref>。在腸道中，腸球菌會搶奪病原菌的生存空間，所以當不小心吃入了病原菌，這些病原菌也沒有辦法留在腸道中，大幅減低了它們的致病力。此外，腸球菌具有抵抗消化液的能力，作為益生菌食用時，因不容易被消化液分解，所以能有更多的菌量到達腸道，使其更容易發揮改善腸道健康的作用；因為這些特性，所以腸球菌是常見的益生菌選擇之一<ref>{{Cite journal|title=Enterococci at the crossroads of food safety?|url=https://www.ncbi.nlm.nih.gov/pubmed/10357269|last=Franz|first=C. M.|last2=Holzapfel|first2=W. H.|date=1999-03-01|journal=International Journal of Food Microbiology|issue=1-2|volume=47|pages=1–24|issn=0168-1605|pmid=10357269|last3=Stiles|first3=M. E.}}</ref>。

早在1980年代，腸球菌就被使用來治療細菌性的腹瀉<ref>{{cite journal|title= Biological properties of SF68, a new approach for the treatment of diarrhoeal diseases|url=|author1=Lewenstein A | author2= Frigerio G | author3= Mangiagli A |journal=Curr Ther Res. |doi=|year=1979|volume=26|issue=|pages=967–981}}</ref><ref>{{cite journal|title= A controlled double-blind study of SF68 strain as a new biological preparation for the treatment of diarrhoea in pediatrics.|url=|author1=Bellomo G | author2= Mangiagli A | author3= Nicastro L |author4=Frigerio G | journal=Curr Ther Res. |doi=|year=1980|volume=28|issue=|pages=927–936}}</ref><ref>{{Cite journal|title=A microbiological investigation on probiotic preparations used for animal feeding|url=https://doi.org/10.1016/s0944-5013(96)80041-3|last=Canganella|first=F.|last2=Gasbarri|first2=M.|journal=Microbiological Research|issue=2|doi=10.1016/s0944-5013(96)80041-3|volume=151|pages=167–175|last3=Massa|first3=S.| display-authors=3|last4=Trovatelli|first4=L.D.}}</ref>，當時被認為是藥物治療以外的另一種選擇，主要因為腸球菌在腸道內生長快速，並可抑制其它致病菌，例如[[大腸桿菌|大腸桿菌]]的生長，因此能減緩腹瀉的症狀。除了細菌性腹瀉，腸球菌也被證實能用來預防藥物型腹瀉<ref>{{cite journal|title= A controlled clinical study on Streptococcus faecium preparation for the prevention of side reactions during long-term antibiotic treatments|url=|author=Borgia, M., Sepe, N., Brancato, V., Costa, G., Simone, P., Borgia, R. |journal=Curr Ther Res. |doi=|year=1982|volume=31|issue=|pages=265–271}}</ref><ref>{{Cite journal|title=Double-blind report on the efficacy of lactic acid-producing Enterococcus SF68 in the prevention of antibiotic-associated diarrhoea and in the treatment of acute diarrhoea|url=https://www.ncbi.nlm.nih.gov/pubmed/2676650|last=Wunderlich|first=P. F.|last2=Braun|first2=L.|date=July 1989|journal=The Journal of International Medical Research|issue=4|doi=10.1177/030006058901700405|volume=17|pages=333–338|issn=0300-0605|pmid=2676650|last3=Fumagalli|first3=I.|last4=D'Apuzzo|first4=V.|last5=Heim|first5=F.|last6=Karly|first6=M.|last7=Lodi|first7=R.|last8=Politta|first8=G.|last9=Vonbank|first9=F.}}</ref>；當服用抗生素時，腸道的菌群會因此失衡，一些致病菌就會趁機繁殖，進而造成腹瀉等症狀，腸球菌可避免服用抗生素時的不良反應發生。所以將具有抗藥性的腸球菌作為藥品，連同抗生素一同使用，達到治療效果的同時，也可以避免副作用的發生<ref>{{Cite journal|title=Towards a compatible probiotic-antibiotic combination therapy: assessment of antimicrobial resistance in the Japanese probiotics|url=https://www.ncbi.nlm.nih.gov/pubmed/20497275|last=Hammad|first=A. M.|last2=Shimamoto|first2=T.|date=October 2010|journal=Journal of Applied Microbiology|issue=4|doi=10.1111/j.1365-2672.2010.04762.x|volume=109|pages=1349–1360|issn=1365-2672|pmid=20497275}}</ref>。

中華民國食品藥物管理署於2017年10月19日公告：預告訂定「糞腸球菌(''Enterococcus faecalis'')及屎腸球菌(''Enterococcus faecium'')不得作為食品原料使用」草案，預定2018年7月實施。因腸球菌菌株變異性大，若要作為食品原料使用，業者必須要提出數據證實安全無虞，經個案審議才有機會使用。屆時規定若正式施行後，經查獲食品使用的原料不符規定者，將可依法開罰<ref>{{Cite journal|title=預告訂定「糞腸球菌(Enterococcus faecalis)及屎腸球菌(Enterococcus faecium)不得作為食品原料使用」草案|url=https://www.fda.gov.tw/tc/newsContent.aspx?cid=5072&id=22492}}</ref>。

=== 食用的健康風險 ===
1998年，美國的一項研究就發現，腸球菌在腸道聚集生長的過程會產生相當可觀的[[自由基|自由基]]，這些自由基很可能導致腸黏膜細胞的不正常增生，進而引發大癌直腸癌的風險<ref>{{Cite journal|title=Prospective case-cohort study of intestinal colonization with enterococci that produce extracellular superoxide and the risk for colorectal adenomas or cancer|url=http://www.nature.com/doifinder/10.1111/j.1572-0241.1998.00710.x|last=Winters|first=Michael D.|last2=Schlinke|first2=Tiffany L.|journal=The American Journal of Gastroenterology|issue=12|doi=10.1111/j.1572-0241.1998.00710.x|volume=93|pages=2491–2500|last3=Joyce|first3=Wendy A.|last4=Glore|first4=Stephen R.|last5=Huycke|first5=Mark M.}}</ref>。

腸球菌具有很強的抗藥性散播能力<ref name = Gilmore_2014>{{Cite book|title=Enterococci: From Commensals to Leading Causes of Drug Resistant Infection|url=https://www.ncbi.nlm.nih.gov/pubmed/24649510|date=2014|publisher=Massachusetts Eye and Ear Infirmary|editor-last=Gilmore|editor-first=Michael S.|location=Boston|pmid=24649510}}</ref><ref name=":1">{{Cite journal|title=Enterococci as probiotics and their implications in food safety|url=https://www.ncbi.nlm.nih.gov/pubmed/21962867|last=Franz|first=Charles M. A. P.|last2=Huch|first2=Melanie|date=2011-12-02|journal=International Journal of Food Microbiology|issue=2|doi=10.1016/j.ijfoodmicro.2011.08.014|volume=151|pages=125–140|issn=1879-3460|pmid=21962867|last3=Abriouel|first3=Hikmate|last4=Holzapfel|first4=Wilhelm|last5=Gálvez|first5=Antonio}}</ref><ref>{{Cite journal|title=Vancomycin-resistant enterococcal infections|url=https://www.ncbi.nlm.nih.gov/pubmed/10706902|last=Murray|first=B. E.|date=2000-03-09|journal=The New England Journal of Medicine|issue=10|doi=10.1056/NEJM200003093421007|volume=342|pages=710–721|issn=0028-4793|pmid=10706902}}</ref>，造成原本可以被殺死的細菌變成殺不死，因此不被認為是[[一般公認安全|一般公認安全]]（Generally Recognized as Safe，GRAS）的菌種<ref name=":2">{{Cite book|url=https://www.worldcat.org/oclc/965781424|last=Murlidhar,|first=Meghwal,|last2=Raj,|first2=Goyal, Megh|last3=S.,|first3=Chavan, Rupesh|isbn=9781771883801|location=Oakville, ON|title=Dairy engineering : advanced technologies and their applications|oclc=965781424}}</ref><ref name=":3">{{Cite journal|title=Variations in clinical presentation of patients with esophageal contraction abnormalities|url=https://www.ncbi.nlm.nih.gov/pubmed/4053917|last=Reidel|first=W. L.|last2=Clouse|first2=R. E.|date=November 1985|journal=Digestive Diseases and Sciences|issue=11|volume=30|pages=1065–1071|issn=0163-2116|pmid=4053917}}</ref>，作為益生菌使用仍有安全上的問題，特別是在細菌感染、免疫低下的患者和老年人身上<ref name=":2" /><ref name=":4">{{Cite journal|title=Molecular Screening of EnterococcusVirulence Determinants and Potential for Genetic Exchange between Food and Medical Isolates|url=http://aem.asm.org/content/67/4/1628|last=Eaton|first=Tracy J.|last2=Gasson|first2=Michael J.|date=2001-04-01|journal=Applied and Environmental Microbiology|issue=4|doi=10.1128/AEM.67.4.1628-1635.2001|volume=67|pages=1628–1635|language=en|issn=0099-2240|pmid=11282615}}</ref><ref name=":5">{{Cite journal|title=Probiotic Enterococcus faecium strain is a possible recipient of the vanA gene cluster|url=https://www.ncbi.nlm.nih.gov/pubmed/11303279|last=Lund|first=B.|last2=Edlund|first2=C.|date=2001-05-01|journal=Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America|issue=9|doi=10.1086/319994|volume=32|pages=1384–1385|issn=1058-4838|pmid=11303279}}</ref>。除了抗藥性的散播能力，腸球菌也可能散播毒性因子<ref name=":4" /><ref name=":5" /><ref name=":6">{{Cite journal|title=Stromal changes in early invasive and non-invasive breast carcinoma: an ultrastructural study|url=https://www.ncbi.nlm.nih.gov/pubmed/3023597|last=Tamimi|first=S. O.|last2=Ahmed|first2=A.|date=September 1986|journal=The Journal of Pathology|issue=1|doi=10.1002/path.1711500108|volume=150|pages=43–49|issn=0022-3417|pmid=3023597}}</ref><ref name=":7">{{Cite journal|title=Enterococci in foods--a conundrum for food safety|url=https://www.ncbi.nlm.nih.gov/pubmed/14596984|last=Franz|first=Charles M. A. P.|last2=Stiles|first2=Michael E.|date=2003-12-01|journal=International Journal of Food Microbiology|issue=2-3|volume=88|pages=105–122|issn=0168-1605|pmid=14596984|last3=Schleifer|first3=Karl Heinz|last4=Holzapfel|first4=Wilhelm H.}}</ref><ref name=":8">{{Cite journal|title=The genus Enterococcus as probiotic: safety concerns|url=http://www.scielo.br/scielo.php?script=sci_abstract&pid=S1516-89132013000300014&lng=en&nrm=iso&tlng=en|last=Araújo|first=Tatiane Ferreira|last2=Ferreira|first2=Célia Lúcia de Luces Fortes|date=June 2013|journal=Brazilian Archives of Biology and Technology|issue=3|doi=10.1590/S1516-89132013000300014|volume=56|pages=457–466|issn=1516-8913}}</ref>，增加了腸球菌在食品應用上的疑慮，故腸球菌作為益生菌原料的安全性必須審慎評估。

腸球菌因抗藥因子和毒性因子的高度散播能力，使腸球菌容易獲得或傳遞這些對健康有風險的因子，最後衍生出藥物殺不死的病菌，造成了治療上的困難，顯示腸球菌對人體健康的潛在危害<ref name=":1" /><ref name=":3" /><ref name=":6" /><ref name=":7" /><ref name=":8" />。因此，考慮到腸球菌感染在人類流行病學上的進展，以及腸球菌對人體健康可能具有的風險，
[[世界衛生組織|世界衛生組織]]（WHO）在2002年提出報告不建議腸球菌作為益生菌提供給人類使用<ref>Probiotics in food: Health and nutritional properties and guidelines for evaluation. ISSN: 0254-4725.</ref>，2007年歐洲食品安全局（EFSA）也認為腸球菌並非屬於合格認定安全（Qualified Presumption of Safety，QPS）的菌種<ref>Introduction of a Qualified Presumption of Safety (QPS) approach for assessment of selected microorganisms referred to EFSA. The EFSA Journal. 2007;587:1–16.</ref><ref>Scientific Opinion on the maintenance of the list of QPS biological agents intentionally added to food and feed (2013 update). EFSA Journal 2013;11(11):3449 [106 pp.].</ref>，2011年[[美國食品藥品監督管理局|美國食品藥品監督管理局]]（FDA）的乳製品指導方針草案<ref>Dietary Supplements: New Dietary Ingredient Notifications and Related Issues: Guidance for Industry. U.S. FDA, Center for Food Safety and Applied Nutrition; August 2016.</ref>也不建議將腸球菌作為益生菌使用。中國<ref>{{Cite journal|title=卫生部关于印发真菌类和益生菌类保健食品评审规定的通知。|url=http://www2.cde.org.tw/CSMA/DocLib2/01.%E4%BF%9D%E5%81%A5%E9%A3%9F%E5%93%81%E8%A8%BB%E5%86%8A%E5%AF%A9%E6%89%B9/21.%E8%A1%9B%E6%B3%95%E7%9B%A3%E7%99%BC%EF%BC%BB2001%EF%BC%BD84%E8%99%9F-%E9%97%9C%E6%96%BC%E5%8D%B0%E7%99%BC%E7%9C%9F%E3%80%8A%E7%9C%9F%E8%8F%8C%E9%A1%9E%E4%BF%9D%E5%81%A5%E9%A3%9F%E5%93%81%E8%A9%95%E5%AF%A9%E8%A6%8F%E5%AE%9A%E3%80%8B%E3%80%81%E3%80%8A%E7%9B%8A%E7%94%9F%E8%8F%8C%E9%A1%9E%E4%BF%9D%E5%81%A5%E9%A3%9F%E5%93%81%E8%A9%95%E5%AF%A9%E8%A6%8F%E5%AE%9A%E3%80%8B%E7%9A%84%E9%80%9A%E7%9F%A5.pdf}}</ref><ref>{{Cite journal|title=卫生部关于印发《可用于食品的菌种名单》的通知。|url=http://www.moh.gov.cn/mohbgt/s10787/201004/47133.shtml}}</ref> 、加拿大<ref>Report submitted to the Natural Health Products Directorate, Health Canada. Nutritech Consulting Winnipeg, Manitoba; March 2005.</ref><ref>{{Cite journal|title=Health Claims - Probiotic Claims | url=http://www.inspection.gc.ca/food/labelling/food-labelling-for-industry/health-claims/eng/1392834838383/1392834887794?chap=9}}</ref>等國也禁止或不建議腸球菌作為益生菌成分。根據許多研究結果及主要國家的安全評估，腸球菌作為益生菌對人體健康的不良影響實無法完全排除，因此禁止或有條件的使用是有其必要性的。

腸球菌專家、美國哈佛大學醫學院的Michael S. Gilmore博士團隊在其所撰寫的《Enterococci》一書中，除了提及美國FDA與歐洲食品安全局不建議使用腸球菌作為益生菌給人類食用之外，更寫到腸球菌必須確定無毒性因子以及必須以活體試驗（in vivo）證明不具有[[基因水平轉移|基因水平轉移]]的能力（會導致抗藥性的散播）才可以作為益生菌食用；然而，到2014年為止，科學界並沒有發現不具基因轉移能力的腸球菌菌株<ref name ="Gilmore_2014"/>。有研究顯示一些從食物分離出的腸球菌可能藏有毒性因子，但毒性的顯現卻並非由特定的毒性因子所掌控，而是由更複雜的過程所導致。<ref name=":1" />。因此，腸球菌作為益生菌使用仍有相當大的爭議，想藉由食用這類益生菌來促進健康的同時，也不應忽視腸球菌對人體健康的不良影響。

== 藥品應用 ==

目前腸球菌應用於醫藥級的藥用益生菌（pharmaceutical probiotics）主要在歐洲與亞洲部分國家通過上市。市面上以屎腸球菌（''E. faecium''）作為藥用益生菌的安全菌株，主要源自於瑞士原料藥廠Cerbios-Pharma SA所研發的''Enterococcus faecium'' SF68®（cernelle 68）菌株。德國、台灣與日本的藥廠則多半以糞腸球菌（''E. faecalis''）研發安全菌株製成藥用的益生菌。

=== 屎腸球菌（''E. faecium''） ===

瑞士Cerbios-Pharma SA藥廠獲得cGMP製程認證，專精於研發與生產醫藥等級的益生菌，主要銷往歐盟各國、美國、日本、韓國等生技市場。在腸球菌的部分，研發''Enterococcus faecium'' SF68®活性屎腸球菌，並通過[[雙盲|雙盲]]臨床藥物測試，用來預防與治療腸道相關的病症<ref>{{ Cite journal|title=Pharmaceutical probiotics based on SF68®|url=http://www.cerbios.ch/Products/Pharmaceutical-probiotics-based-on-SF68-R}}</ref>。

法國Sanofi藥廠的Bioflorin®<ref>{{ Cite journal|title=Bioflorin®: Das Probiotikum für die ganze Familie|url= http://www.bioflorin.ch/de/index.html}}</ref>、巴基斯坦RG Pharmacutica藥廠的Newflora®<ref>{{ Cite journal|title= Peadiatri Care Newflora®|url= http://www.rgp.com.pk/peadiatri-care-newflora.html|journal= |author= |access-date= 2017-09-03|archive-url= https://web.archive.org/web/20170903205445/http://www.rgp.com.pk/peadiatri-care-newflora.html|archive-date= 2017-09-03|dead-url= yes}}</ref><ref>{{ Cite journal|title=Cerbios NewfloraTM|url=http://www.cerbios.ch/Products/Newflora}}</ref>與韓國東丘（DongKoo）藥廠的Ventrux<ref>{{ Cite journal|title=Ventrux|url=http://www.dongkoo.com/eng/product/form/pro/210}}</ref>、Bio-Balance<ref>{{ Cite journal|title=倍益生|url=http://www.allyeast.com/Product.aspx?pid=B0009|journal=|author=|access-date=2017-09-03|archive-url=https://web.archive.org/web/20170903210725/http://www.allyeast.com/Product.aspx?pid=B0009|archive-date=2017-09-03|dead-url=yes}}</ref>都是使用瑞士Cerbios-Pharma SA藥廠的SF68®菌株。'''台灣有廠商輸入韓國東丘藥廠的衛樂舒散（衛署藥輸字第021237號），衛樂舒藥品仿單上為SF68®菌株<ref>{{ Cite journal|title=Ventrux powder|url= https://drugs.olc.tw/drugs/view/56f45d4d-09dc-4a76-8da6-0d69d38a10d1}}</ref>，然而衛福部食藥署的許可證內容卻標示菌種為糞腸球菌（''S. faecalis''）<ref>{{ Cite journal|title=衛樂舒散許可證詳細內容|url=http://www.fda.gov.tw/MLMS/(S(zhayg3j2oyozxi45fx41gi55))/H0001D.aspx?Type=Lic&LicId=02021237}}</ref>，此出入仍有待查證當中。'''

=== 糞腸球菌（''E. faecalis''） ===

德國SymbioPharm GmbH藥廠研發''E. faecalis'' DSM 16440菌株<ref>{{Cite journal|title= A mixture of Escherichia coli (DSM 17252) and Enterococcus faecalis (DSM 16440) for treatment of the irritable bowel syndrom
\e--a randomized controlled trial with primary care physicians|url= https://www.ncbi.nlm.nih.gov/pubmed/?term=DSM+16440|author= Enck P, Zimmermann K, Menke G, Müller-Lissner S, Martens U, Klosterhalfen S|date=Oct 2008|journal= Neurogastroenterol Motil|issue=10|volume=20|pages=1103-9|doi= 10.1111/j.1365-2982.2008.01156.x}}</ref>，開發Symbioflor® 1<ref>{{Cite journal|title= Symbioflor® 1|url=https://www.symbiopharm.de/en/products/symbioflor-1.html}}</ref>與Pro-Symbioflor®<ref>{{Cite journal|title= Pro-Symbioflor®|url=https://www.symbiopharm.de/en/products/pro-symbioflor.html}}</ref>等藥用益生菌，除了可改善腸胃不適的症狀，也可強化免疫系統，緩解呼吸道發炎，例如鼻竇炎與支氣管炎的症狀。

台灣製造生產含有腸球菌的藥品有百賜益錠Bio-Three Tablets
<ref>{{Cite journal|title=百賜益錠Bio-Three Tablets|url= https://drugs.olc.tw/drugs/view/54edefe2-8604-4fdd-b613-4939d38a10d1}}</ref>及"大豐"固兒美顆粒Goodmin Granules "T.F."<ref>{{Cite journal|title= "大豐"固兒美顆粒Goodmin Granules "T.F."|url= https://drugs.olc.tw/drugs/view/549293d4-6084-425b-a459-1cffd38a10d1}}</ref>，主要用於整腸與治療消化不良等腸道不適症狀<ref>{{Cite journal|title= Effectiveness of probiotic therapy for the prevention of relapse in patients with inactive ulcerative colitis |url= https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4438034|author= Yoshimatsu Y, Yamada A, Furukawa R, Sono K, Osamura A, Nakamura K, Aoki H, Tsuda Y, Hosoe N, Takada N, Suzuki Y |date=2015 May 21|journal=World J Gastroenterol|issue=21| volume=19|pages=5985-94| doi=10.3748/wjg.v21.i19.5985|}}</ref>。

武田製藥的新ビオフェルミンS（欣表飛鳴）<ref>{{Cite journal|title= 新ビオフェルミンS|url= http://www.biofermin.co.jp/products/biofermin_s/}}</ref>也含有糞腸球菌，具有調整消化及整腸的功效。

=== 抗性腸球菌藥品 ===

武田製藥的ビオフェルミンR（表飛鳴，菌株129 BIO 3B-R）<ref>{{Cite journal|title=ビオフェルミンR |url=http://www.biofermin.co.jp/iryo/pdf/bfr_if_2013_3.pdf </ref><ref>{{Cite journal|title=衛署藥輸字第020043號 表飛鳴樂散|url=http://www.fda.gov.tw/MLMS/ShowFile.aspx?LicId=02020043&Seq=014&Type=9</ref>成分含有耐性的糞腸球菌（''E. faecalis''），用於改善投與抗生素、[[化學療法|化學療法]]製劑時，腸內菌叢異常所引起的症狀，提高對害菌的殺菌效果，進而減少抗生素的使用量，以防止副作用產生。

'''抗性藥品的抗藥性並不會轉移至人體其他菌叢。'''ビオフェルミンR即特別強調其抗藥性並非由[[質粒|質粒]]（plasmid）表現，而是由染色體進行混合培養的結果，因此抗藥性不會轉移至腸道的大腸桿菌及腸球菌等正常菌叢當中。由於其不會導致治療使用的抗生素失去活性，因此即使抗菌劑存在也會增殖，經由產生乳酸，可改善腸內菌叢的異常，發揮整腸的作用。

== 作為飼料添加物 ==

目前歐洲食品安全局規定腸球菌''E. faecium''使用在動物飼料，須通過相關的安全評估，包括了不得檢出三種毒性因子和DNA標記：IS''16''、Esp、''hyl''-like，以及氨苄青黴素（ampicillin）的最低抑菌濃度（MIC）不得超過2 mg/L，若不符合上述的檢驗標準，則認定為不安全，此腸球菌不可使用於飼料添加物當中<ref>{{Cite journal|title=Guidance on the safety assessment of Enterococcus faecium in animal nutrition|url=http://onlinelibrary.wiley.com/doi/10.2903/j.efsa.2012.2682/abstract|last=EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP)|date=2012-05-01|journal=EFSA Journal|issue=5|doi=10.2903/j.efsa.2012.2682|volume=10|pages=n/a–n/a|language=en|issn=1831-4732}}</ref>。

== 水質標準評估 ==

水質中的腸球菌標準非常嚴格，例如在夏威夷州和美國的大部分地區，其海灘周圍的水域是每100毫升水中，五個星期的平均值不得超過35[[菌落形成單位|菌落形成單位]]（CFU）的腸球菌，否則該地區可能會發布警告，要求民眾遠離海灘<ref name=Hawaii_DOH>{{cite web | title=Clean Water Branch | work=Hawaii State Department of Health | url=http://gen.doh.hawaii.gov/sites/har/AdmRules1/11-54.pdf | accessdate=2012-05-18 | deadurl=yes | archiveurl=https://web.archive.org/web/20111111031411/http://gen.doh.hawaii.gov/sites/har/AdmRules1/11-54.pdf | archivedate=2011-11-11 }}</ref>。2004年，腸球菌更取代了糞大腸菌群和大腸桿菌，成為新的美國聯邦公共鹽水和淡水海域水質標準<ref name="Water Quality Standards for Coastal and Great Lakes Recreation Waters">{{cite web|title=Water Quality Standards for Coastal and Great Lakes Recreation Waters | url=http://www.epa.gov/fedrgstr/EPA-WATER/2004/July/Day-09/w15614.htm|publisher=EPA|accessdate=7/9/2004}}</ref>。

中華民國的海灘水質也是參考香港及美國，主要以甲類海域之海洋環境品質標準—大腸桿菌群之菌落數在1000 CFU/100mL以下（以下簡稱「符合甲類」）為判定依據。符合甲類者，再以腸球菌群區分為「優良」或「普通」。當大腸桿菌群 ≦ 1000 CFU/100mL，且腸球菌群 ≦ 50 CFU/100mL，水質標準為「'''優良'''」。當大腸桿菌群 ≦1000 CFU/100mL，但腸球菌群＞50 CFU/100mL，水質標準為「'''普通'''」。若大腸桿菌群＞1000 CFU/100mL，則「'''不宜親水活動'''」
<ref>{{cite web|title=行政院環保署-全國環境水質監測資訊網-海灘水質檢測標準 | url=https://wq.epa.gov.tw/Code/Theme/BeachQuality.aspx?Tabs=4}}</ref>。

== 實驗室檢驗 ==

腸球菌通常會在羊血瓊脂（sheep's blood agar）上呈現γ-溶血反應<ref name="Sherris">{{cite book | editor = Ryan KJ, Ray CG | title = Sherris Medical Microbiology | edition = 4th | pages = 294–5 |publisher = McGraw Hill | year = 2004 | isbn = 0-8385-8529-9 }}</ref>。

== 参考文献 ==
{{Reflist|30em}}

{{-}}
{{Bacteria classification}}
{{Gram-positive firmicutes diseases}}

[[Category:革兰氏阳性菌|Category:革兰氏阳性菌]]
[[Category:病原菌|Category:病原菌]]
[[Category:厚壁菌門|Category:厚壁菌門]]